Cargando…
GLP-1 Receptor Agonists: Nonglycemic Clinical Effects in Weight Loss and Beyond
OBECTIVE: Glucagon-like peptide-1 (GLP-1) receptor agonists are indicated for treatment of type 2 diabetes since they mimic the actions of native GLP-1 on pancreatic islet cells, stimulating insulin release, while inhibiting glucagon release, in a glucose-dependent manner. The observation of weight...
Autores principales: | Ryan, Donna, Acosta, Andres |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4692091/ https://www.ncbi.nlm.nih.gov/pubmed/25959380 http://dx.doi.org/10.1002/oby.21107 |
Ejemplares similares
-
GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
por: Zhao, Xin, et al.
Publicado: (2021) -
Nonglycemic Outcomes of Antidiabetic Medications
por: Morse, Christopher, et al.
Publicado: (2019) -
1982. GLP-1 Receptor Agonists Promote Weight Loss Among People with HIV
por: Nguyen, Quynh P, et al.
Publicado: (2023) -
FRI078 Real-World Weight Loss Outcomes And Safety Of Tirzepatide, A Novel Dual GIP And GLP-1 Receptor Agonist
por: Fansa, Sima, et al.
Publicado: (2023) -
The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors
por: Kim, Na-Hyung, et al.
Publicado: (2014)